Some Announcements! (And my Top 10 Positions as of November 1, 2024.)

Hello all!

I have a couple quick and exciting announcements.

First, I alluded to some health programs I was having last month. Well, I figured out the root cause. I have Celiac Disease! Wow, I was surprised. I found out a couple days after publishing last month and I have adhered to a strict gluten-free diet since then. I am feeling much much better and have more energy, I’m working out five times a week, and gaining a lot of muscle. But really want this all means for you is I’m ready to start writing a lot more with that extra energy.

And I do miss pastries and high quality bread.

I miss you. (Source: Dr. Schar Institute.)

I also decided I am going to be starting a paid tier to this Substack. It will go live in mid-November. I understand you might have a lot of questions about why now and what the content will be so I will do a FAQ post in a week to answer all those questions. Stay tuned, I think it’s going to be really exciting and I finally have some direction for where I want to take this newsletter.

But for now here is some monthly free content: My current Top 10 positions by dollar amount as of pre-market open November 1, 2024:

1. Evolus (EOLS)

2. Apellis (APLS)

3. Delcath (DCTH)

4. Edgewise Therapeutics (EWTX)

5. scPharmaceuticals (SCPH)

6. Insulet (PODD)

7. Vyne Therapeutics (VYNE)

8. Arcutis (ARQT)

9. SpringWorks Therapeutics (SWTX)

10. Celcuity (CELC)

Looking at this list above, 7 of the names are commercial-stage (EOLS, APLS, DCTH, SCPH, PODD, ARQT, SWTX) and only 3 are clinical-stage biotechs (EWTX, VYNE, CELC).

I still think the value to be had right now in biotech is in the later stage names that are having impressive launches. And this round of earnings calls will be huge to see who is continuing to execute on their current launch trajectories. My thesis will be tested very shortly but I think the names on the list all trade at very reasonable valuations considering the launch catalysts over the next 12 months.

More to come on all seven of these in paid articles. In fact, I guess it will be no surprise that my first paid post will be a summation of at least 15 earnings call transcripts and how it changes my perception of each company. Look for that in mid-November and like I said before that there will be a FAQ post about subscribing to the paid tier, which will be very reasonably priced compared to most investment research services. Think $10/month to start. ☺️ And for that you will get multiple pieces of content per month. I think it will make people happy and keep me on track with publishing on a regular schedule and really committing to this platform vs. Twitter which has become somewhat unusable aside from breaking news and the few accounts left trying to give insightful takes.

Look for much more on all of the above names and some new ideas coming soon. I promise I have been hard at work writing!

Thanks for reading,

Matt